Gilead profit beats Street expectations on COVID and HIV sales
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Gilead Sciences shares gain after topping expectations despite lower remdesivir sales
February 3, 2023 9:46 AM ESTGilead Sciences (NASDAQ: GILD) shares rallied in early Friday trading in reaction to the company's latest earnings report, which saw it beat top and bottom-line consensus expectations.
The biopharmaceutical company posted fourth-quarter earnings of $1.67 per share, $0.17 above the analyst consensus estimate of $1.50, while revenue for the quarter came in at $7.4 billion, beating expectations of $6.66 billion.
The company's revenue increased year-over-year, primarily due to increased sales in Oncology, HIV, and hepatitis C virus. However, this was partially offset by... More
